INM
Price
$3.20
Change
-$0.12 (-3.61%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
3.86M
MDXG
Price
$6.33
Change
-$0.08 (-1.25%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
935.69M
61 days until earnings call
Interact to see
Advertisement

INM vs MDXG

Header iconINM vs MDXG Comparison
Open Charts INM vs MDXGBanner chart's image
InMed Pharmaceuticals
Price$3.20
Change-$0.12 (-3.61%)
Volume$1.9K
Capitalization3.86M
MiMedx Group
Price$6.33
Change-$0.08 (-1.25%)
Volume$7.19K
Capitalization935.69M
INM vs MDXG Comparison Chart
Loading...
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INM vs. MDXG commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INM is a StrongBuy and MDXG is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (INM: $3.20 vs. MDXG: $6.34)
Brand notoriety: INM and MDXG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INM: 24% vs. MDXG: 63%
Market capitalization -- INM: $3.86M vs. MDXG: $935.69M
INM [@Biotechnology] is valued at $3.86M. MDXG’s [@Biotechnology] market capitalization is $935.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INM’s FA Score shows that 0 FA rating(s) are green whileMDXG’s FA Score has 1 green FA rating(s).

  • INM’s FA Score: 0 green, 5 red.
  • MDXG’s FA Score: 1 green, 4 red.
According to our system of comparison, MDXG is a better buy in the long-term than INM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INM’s TA Score shows that 7 TA indicator(s) are bullish while MDXG’s TA Score has 4 bullish TA indicator(s).

  • INM’s TA Score: 7 bullish, 2 bearish.
  • MDXG’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, INM is a better buy in the short-term than MDXG.

Price Growth

INM (@Biotechnology) experienced а +30.61% price change this week, while MDXG (@Biotechnology) price change was -3.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

INM is expected to report earnings on May 12, 2025.

MDXG is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDXG($936M) has a higher market cap than INM($3.86M). MDXG has higher P/E ratio than INM: MDXG (23.46) vs INM (0.01). MDXG YTD gains are higher at: -33.264 vs. INM (-35.076). MDXG has higher annual earnings (EBITDA): 62.1M vs. INM (-7.44M). MDXG has more cash in the bank: 106M vs. INM (3.42M). INM has less debt than MDXG: INM (949K) vs MDXG (18.7M). MDXG has higher revenues than INM: MDXG (352M) vs INM (4.83M).
INMMDXGINM / MDXG
Capitalization3.86M936M0%
EBITDA-7.44M62.1M-12%
Gain YTD-35.076-33.264105%
P/E Ratio0.0123.460%
Revenue4.83M352M1%
Total Cash3.42M106M3%
Total Debt949K18.7M5%
FUNDAMENTALS RATINGS
INM vs MDXG: Fundamental Ratings
INM
MDXG
OUTLOOK RATING
1..100
9575
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
10078
SMR RATING
1..100
9541
PRICE GROWTH RATING
1..100
6063
P/E GROWTH RATING
1..100
8212
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INM's Valuation (39) in the null industry is in the same range as MDXG (67) in the Biotechnology industry. This means that INM’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's Profit vs Risk Rating (78) in the Biotechnology industry is in the same range as INM (100) in the null industry. This means that MDXG’s stock grew similarly to INM’s over the last 12 months.

MDXG's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for INM (95) in the null industry. This means that MDXG’s stock grew somewhat faster than INM’s over the last 12 months.

INM's Price Growth Rating (60) in the null industry is in the same range as MDXG (63) in the Biotechnology industry. This means that INM’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for INM (82) in the null industry. This means that MDXG’s stock grew significantly faster than INM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMMDXG
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 17 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WGGNX11.12N/A
N/A
William Blair Global Leaders N
FGDTX36.55N/A
N/A
Fidelity Advisor Gold M
PQSAX25.02N/A
N/A
Virtus KAR Small-Cap Value A
WFPRX47.42N/A
N/A
Allspring Special Mid Cap Value R6
GCPAX19.70N/A
N/A
Gateway Equity Call Premium A

INM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INM has been loosely correlated with TTNP. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INM jumps, then TTNP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INM
1D Price
Change %
INM100%
-10.24%
TTNP - INM
43%
Loosely correlated
+0.84%
EYEN - INM
39%
Loosely correlated
-1.42%
OMER - INM
36%
Loosely correlated
+6.37%
VTYX - INM
31%
Poorly correlated
N/A
PULM - INM
30%
Poorly correlated
+4.43%
More

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
-0.93%
AXON - MDXG
47%
Loosely correlated
+2.76%
VCYT - MDXG
42%
Loosely correlated
+2.98%
ARRY - MDXG
39%
Loosely correlated
-0.43%
RAPT - MDXG
38%
Loosely correlated
+3.24%
INM - MDXG
38%
Loosely correlated
-10.24%
More